Compare Meta Platforms Inc (META) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs ResMed Inc. — how do they compare? Meta Platforms Inc trades at $601 (market cap $1.52T), while ResMed Inc. trades at $223.62 (market cap $31.92B). The key difference: Meta Platforms Inc is far larger — about 47.6× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.2%). Which is the better fit depends on your goals.
| META | RMD | |
|---|---|---|
Market Cap | $1.52T | $31.92B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $293.73 |
52-Week Low | $525.72 | $182.82 |
Enterprise Value | $1.54T | $31.28B |
Dividend Yield | 0.35% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $594.92, up 0.48% with strong fundamentals including 81.75% gross margins and 29.84% net income margin. Recent Q1 2026 earnings beat expectations ($10.44 vs $6.70), though Q2 2026 missed. Technical indicators show bearish momentum with RSI at 96.23 suggesting overbought conditions. The company launched Muse Spark AI model and faces ongoing legal challenges regarding youth addiction lawsuits.
Outlook remains positive with analyst consensus price target of $761.95 (28% upside) and 79% buy ratings. Key risks include regulatory lawsuits, aggressive AI capex spending ($102B in 2025), and competitive pressures. Revenue growth continues at 22% year-over-year to $201B, supporting long-term investment thesis despite near-term technical weakness.
ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.
Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
